Subscribe to RSS
DOI: 10.1055/s-0032-1309003
The Antidepressant Agomelatine in Daily Practice: Results of the Non-Interventional Study VIVALDI
Publication History
received 19 December 2011
revised 05 March 2012
accepted 05 March 2012
Publication Date:
16 May 2012 (online)
![](https://www.thieme-connect.de/media/pharmaco/201207/lookinside/thumbnails/10.1055-s-0032-1309003-1.jpg)
Abstract
Introduction:
The non-interventional study VIVALDI was carried out to evaluate the treatment with agomelatine, an innovative antidepressant, in routine practice.
Methods:
665 psychiatrists treated 3 317 patients over 12 weeks with agomelatine and documented antidepressant effects via svMADRS, CGI scale and CircScreen questionnaire. Subgroups with severe depression (svMADRS ≥30) and elderly patients (≥65 years) were also analyzed.
Results:
In the total population, svMADRS total score decreased from 30.6 at baseline to 12.8 at final visit, in severely depressed patients from 36.7 to 14.7, in elderly patients from 29.0 to 12.2. In total 65.8% of patients could be classified as responders (≥50% decrease in svMADRS total score) and 54.8% as remitters (svMADRS ≤12). Daytime sleepiness was ameliorated in 78.2% of patients. Adverse drug reactions were reported for 10.0%, 8.9% and 10.1% of patients in total population, severely ill and elderly patients, respectively.
Discussion:
In this study, the antidepressant effects, improvement of circadian rhythm disorders and good tolerability of agomelatine were observed in unselected depressed patients, including multimorbid elderly and severely depressed patients under routine practice.
-
References
- 1 Alonso J, Angermeyer MC, Bernert S et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004; 21-27
- 2 Kessler RC, Berglund P, Demler O et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289: 3095-3105
- 3 Sobocki P, Jonsson B, Angst J et al. Cost of depression in Europe. J Ment Health Policy Econ 2006; 9: 87-98
- 4 Wehr TA, Wirz-Justice A. Circadian rhythm mechanisms in affective illness and in antidepressant drug action. Pharmacopsychiatria 1982; 15: 31-39
- 5 Wirz-Justice A. Biological rhythm disturbances in mood disorders. Int Clin Psychopharmacol 2006; 21 (Suppl. 01) S11-S15
- 6 Nutt D, Wilson S, Paterson L. Sleep disorders as core symptoms of depression. Dialogues Clin Neurosci 2008; 10: 329-336
- 7 Buysse D, Angst J, Gamma A et al. Prevalence, course, and comorbidity of insomnia and depression in young adults. Sleep 2008; 31: 473-480
- 8 Riemann D, Voderholzer U. Primary insomnia: a risk factor to develop depression. J Affect Disord 2003; 76: 255-259
- 9 Millan MJ, Gobert A, Lejeune F et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306: 954-964
- 10 Masana MI, Benloucif S, Dubocovich ML. Circadian rhythm of mt1 melatonin receptor expression in the suprachiasmatic nucleus of the C3H/HeN mouse. J Pineal Res 2000; 28: 185-192
- 11 Neu JM, Niles LP. A marked diurnal rhythm of melatonin ML1A receptor mRNA expression in the suprachiasmatic nucleus. Brain Res Mol Brain Res 1997; 49: 303-306
- 12 Poirel VJ, Masson-Pevet M, Pevet P et al. MT1 melatonin receptor mRNA expression exhibits a circadian variation in the rat suprachiasmatic nuclei. Brain Res 2002; 946: 64-71
- 13 Racagni G, Riva MA, Molteni R et al. Mode of action of agomelatine: synergy between melatonergic and 5-HT(2C) receptors. World J Biol Psychiatry 2011; 12: 574-587
- 14 Kasper S, Hajak G, Wulff K et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry 2010; 71: 109-120
- 15 Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007; 10: 661-673
- 16 Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006; 16: 93-100
- 17 Kennedy SH, Rizvi S, Fulton K et al. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008; 28: 329-333
- 18 Kasper S. Superior efficacy results of agomelatine in a pooled analysis versus SSRI SNRI. Eur Neuropsychopharmacol 2010; 20 (Suppl. 03) S348
- 19 Hale A, Corral R, Mencacci C et al. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. Int Clin Psychopharmacol 2010; 25: 305-314
- 20 Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007; 68: 1723-1732
- 21 Quera-Salva MA, Hajak G, Philip P et al. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int Clin Psychopharmacol 2011; 26: 252-262
- 22 Kennedy SH, Rizvi S. Agomelatine in the treatment of major depressive disorder − review article. CNS Drugs 2010; 24: 479-499
- 23 Möller HJ, Schnitker J. Prospective study using a modified Montgomery-Asberg Depression Scale. Nervenarzt 2007; 78: 685-690
- 24 Laredo J, Quera Salva MA, Falissard B et al. Screening of sleep and circadian rhythms in major depression. J Sleep Res 2002; 11: 132-133
- 25 Loo H, Hale A, D’Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17: 239-247
- 26 Goodwin GM, Emsley R, Rembry S et al. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70: 1128-1137
- 27 Goodwin GM, Rouillon F, Emsley R. Long-term treatment with agomelatine:prevention of relapse in patients with major depressive disorder over 10 months. Eur Neuropsychopharmacol 2008; 18: S338
- 28 Kim JM, Kim SY, Stewart R et al. Improvement within 2 weeks and later treatment outcomes in patients with depressive disorders: the CRESCEND study. J Affect Disord 2011; 129: 183-190
- 29 Montgomery SA, Kennedy SH, Burrows GD et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004; 19: 271-280
- 30 Laux G, Studiengruppe V. Antidepressive Therapie mit Agomelatin in der Facharztpraxis. Ergebnisse der VIVALDI-Studie. Psychopharmakotherapie 2011; 18: 18-26
- 31 BfArM PEI. Gemeinsame Empfehlungen des Bundesinstituts für Arzneimittel und Medizinprodukte und des Paul-Ehrlich-Instituts zur Planung. Durchführung und Auswertung von Anwendungsbeobachtungen (Entwurfsfassung vom 9. Mai 2007 zur Kommentierung durch die Fachöffentlichkeit) 2007